key: cord-0855919-6o0tj4a0
authors: Anand, Krishnan; Vadivalagan, Chithravel; Joseph, Jitcy Saji; Singh, Sachin Kumar; Gulati, Monica; Shahbaaz, Mohd; Abdellattif, Magda H.; Prasher, Parteek; Gupta, Gaurav; Chellappan, Dinesh Kumar; Dua, Kamal
title: A novel nano therapeutic using convalescent plasma derived exosomal (CP(Exo)) for COVID-19: A combined hyperactive immune modulation and diagnostics
date: 2021-05-13
journal: Chem Biol Interact
DOI: 10.1016/j.cbi.2021.109497
sha: 0e60984eeb1b1d37c65765e2764c04b0b4d0c3da
doc_id: 855919
cord_uid: 6o0tj4a0

Extracellular vesicles like exosomes are important therapeutic tactics for treating COVID -19. By utilizing convalescent plasma derived exosomes (CP(Exo)) from COVID-19 recovered persistence could accelerate the treatment strategies in the current state of affairs. Adequate literature has shown that administering the exosome to the in vivo system could be beneficial and could target the pathogens in an effective and precise manner. In this hypothesis we highlight the CP(Exo) instead of convalescent plasma (CP), perhaps to dispense of exosomes are gratified and it’s more effectively acquired immune response conferral through antibodies. COVID-19 convalescent plasma has billions of exosomes and it has aptitudes to carry molecular constituents like proteins, lipids, RNA and DNA, etc. Moreover, exosomes are capable of recognizing antigens with adequate sensitivity and specificity. Many of these derivatives could trigger an immune modulation into the cells and act as an epigenetic inheritor response to target pathogens through RNAs. COIVID-19 resistance activated plasma-derived exosomes are either responsible for the effects of plasma beyond the contained immune antibodies or could be inhibitory. The proposed hypothesis suggests that preselecting the plasma-derived antibodies and RNAs merged exosomes would be an optimized therapeutic tactic for COVID-19 patients. We suggest that, the CP(Exo) has a multi-potential effect for treatment efficacy by acting as immunotherapeutic, drug carrier, and diagnostic target with noncoding genetic materials as a biomarker.

INTRODUCTION 76 COVID -19, is identified as a major pandemic disease in the last 10 over the previous 77 decades of global history which is a serious respiratory inflammation by the SARS-CoV-2 78 virus [1, 2] . As of September 2020, more than 2.6 million confirmed cases of COVID-19 79 infections were recorded, which included 876,616 mortalities [3] . Several economists stated Expected biomaterial for drug delivery in the biological system is based on the 123 transfer membrane activity and translocation potential during treatment. Based on these 124 characteristics, we recommended the appropriate biomaterial with size is about less than 100 125 nm like extracellular vesicles or exosomes. Plasma derived exosomal dimensions are 126 between 60 to 100 nm and it has multi-potent features like optimistic size will be used for 127 drug translocation, and inbound carrier of genetic materials would be best therapeutic 128 biomarkers. 

Immunological considerations for COVID-19 vaccine strategies

Advanced drug delivery systems can assist in targeting